Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Clinical trial NCT05898256 · UNKNOWN

Trial details

NCT number: NCT05898256
Sponsor: Guangxi Medical University
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma Immune Checkpoint Inhibitors

Start date: 2023-08-01
Primary completion: 2024-07-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.